BACKGROUND: Combining radioactive colloids and a near-infrared (NIR) fluorophore permits preoperative planning and intraoperative localization of deeply located sentinel lymph nodes (SLNs) with direct optical guidance by a single lymphatic tracer. The aim of this clinical trial was to evaluate and optimize a hybrid NIR fluorescence and radioactive tracer for SLN detection in patients with breast cancer. METHODS: Patients with breast cancer undergoing SLN biopsy were enrolled. The day before surgery, a periareolar injection of indocyanine green (ICG)-99mTc-radiolabelled nanocolloid was administered and a lymphoscintigram acquired. Blue dye was injected immediately before surgery. Intraoperative SLN localization was performed using a γ probe and the Mini-FLARE™ NIR fluorescence imaging system. Patients were divided into two dose groups, with one group receiving twice the particle density of ICG and nanocolloid, but the same dose of radioactive 99mTc. RESULTS: Thirty-two patients were enrolled in the trial. At least one SLN was identified before and during operation. All 48 axillary SLNs could be detected by γ tracing and NIR fluorescence imaging, but only 42 of them stained blue. NIR fluorescence imaging permitted detection of lymphatic vessels draining to the SLN up to 29 h after injection. Doubling the particle density did not yield a difference in fluorescence intensity (median 255 (range 98-542) versus 284 (90-921) arbitrary units; P = 0.590) or signal-to-background ratio (median 5·4 (range 3·0-15·4) versus 4·9 (3·5-16·3); P = 1·000) of the SLN. CONCLUSION: The hybrid NIR fluorescence and radioactive tracer permitted accurate preoperative and intraoperative detection of the SLNs in patients with breast cancer. REGISTRATION NUMBER: NTR3685 (Netherlands Trial Register; http://www.trialregister.nl).
BACKGROUND: Combining radioactive colloids and a near-infrared (NIR) fluorophore permits preoperative planning and intraoperative localization of deeply located sentinel lymph nodes (SLNs) with direct optical guidance by a single lymphatic tracer. The aim of this clinical trial was to evaluate and optimize a hybrid NIR fluorescence and radioactive tracer for SLN detection in patients with breast cancer. METHODS:Patients with breast cancer undergoing SLN biopsy were enrolled. The day before surgery, a periareolar injection of indocyanine green (ICG)-99mTc-radiolabelled nanocolloid was administered and a lymphoscintigram acquired. Blue dye was injected immediately before surgery. Intraoperative SLN localization was performed using a γ probe and the Mini-FLARE™ NIR fluorescence imaging system. Patients were divided into two dose groups, with one group receiving twice the particle density of ICG and nanocolloid, but the same dose of radioactive 99mTc. RESULTS: Thirty-two patients were enrolled in the trial. At least one SLN was identified before and during operation. All 48 axillary SLNs could be detected by γ tracing and NIR fluorescence imaging, but only 42 of them stained blue. NIR fluorescence imaging permitted detection of lymphatic vessels draining to the SLN up to 29 h after injection. Doubling the particle density did not yield a difference in fluorescence intensity (median 255 (range 98-542) versus 284 (90-921) arbitrary units; P = 0.590) or signal-to-background ratio (median 5·4 (range 3·0-15·4) versus 4·9 (3·5-16·3); P = 1·000) of the SLN. CONCLUSION: The hybrid NIR fluorescence and radioactive tracer permitted accurate preoperative and intraoperative detection of the SLNs in patients with breast cancer. REGISTRATION NUMBER: NTR3685 (Netherlands Trial Register; http://www.trialregister.nl).
Authors: Anne C van Leeuwen; Tessa Buckle; Gavin Bendle; Lenka Vermeeren; Renato Valdés Olmos; Henk G van de Poel; Fijs W B van Leeuwen Journal: J Biomed Opt Date: 2011 Jan-Feb Impact factor: 3.170
Authors: Giorgio Zavagno; Gian Luca De Salvo; Giuliano Scalco; Fernando Bozza; Luca Barutta; Paola Del Bianco; Marco Renier; Carlo Racano; Paolo Carraro; Donato Nitti Journal: Ann Surg Date: 2008-02 Impact factor: 12.969
Authors: Tessa Buckle; Anne C van Leeuwen; Patrick T K Chin; Hans Janssen; Sara H Muller; Jos Jonkers; Fijs W B van Leeuwen Journal: Nanotechnology Date: 2010-08-06 Impact factor: 3.874
Authors: Chulhong Kim; Todd N Erpelding; Konstantin Maslov; Ladislav Jankovic; Walter J Akers; Liang Song; Samuel Achilefu; Julie A Margenthaler; Michael D Pashley; Lihong V Wang Journal: J Biomed Opt Date: 2010 Jul-Aug Impact factor: 3.170
Authors: Marieke E Straver; Philip Meijnen; Geertjan van Tienhoven; Cornelis J H van de Velde; Robert E Mansel; Jan Bogaerts; Nicole Duez; Luigi Cataliotti; Jean H G Klinkenbijl; Helen A Westenberg; Huub van der Mijle; Marko Snoj; Coen Hurkmans; Emiel J T Rutgers Journal: Ann Surg Oncol Date: 2010-03-19 Impact factor: 5.344
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: Quirijn R J G Tummers; Leonora S F Boogerd; Wobbe O de Steur; Floris P R Verbeek; Martin C Boonstra; Henricus J M Handgraaf; John V Frangioni; Cornelis J H van de Velde; Henk H Hartgrink; Alexander L Vahrmeijer Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: Sergi Vidal-Sicart; Fijs W B van Leeuwen; Nynke S van den Berg; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-22 Impact factor: 9.236
Authors: Avnesh S Thakor; Jesse V Jokerst; Pejman Ghanouni; Jos L Campbell; Erik Mittra; Sanjiv S Gambhir Journal: J Nucl Med Date: 2016-10-13 Impact factor: 10.057
Authors: Funda Meric-Bernstam; John C Rasmussen; Savitri Krishnamurthy; I-Chih Tan; Banghe Zhu; Jamie L Wagner; Gildy V Babiera; Elizabeth A Mittendorf; Eva M Sevick-Muraca Journal: Biomed Opt Express Date: 2013-12-13 Impact factor: 3.732
Authors: Floris P R Verbeek; Susan L Troyan; J Sven D Mieog; Gerrit-Jan Liefers; Lorissa A Moffitt; Mireille Rosenberg; Judith Hirshfield-Bartek; Sylvain Gioux; Cornelis J H van de Velde; Alexander L Vahrmeijer; John V Frangioni Journal: Breast Cancer Res Treat Date: 2013-12-13 Impact factor: 4.872
Authors: Floris P R Verbeek; Quirijn R J G Tummers; Daphne D D Rietbergen; Alexander A W Peters; Boudewijn E Schaafsma; Cornelis J H van de Velde; John V Frangioni; Fijs W B van Leeuwen; Katja N Gaarenstroom; Alexander L Vahrmeijer Journal: Int J Gynecol Cancer Date: 2015-07 Impact factor: 3.437